Cellectar Biosciences (CLRB) Competitors $4.99 +0.02 (+0.40%) Closing price 04:00 PM EasternExtended Trading$5.07 +0.08 (+1.60%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. BDRX, AKTX, TELO, COEP, HYPD, OKUR, MAAQ, KZR, RNTX, and CALCShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Biodexa Pharmaceuticals (BDRX), Akari Therapeutics (AKTX), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), Hyperion DeFi (HYPD), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors Biodexa Pharmaceuticals Akari Therapeutics Telomir Pharmaceuticals Coeptis Therapeutics Hyperion DeFi OnKure Therapeutics Mana Capital Acquisition Kezar Life Sciences Rein Therapeutics CalciMedica Cellectar Biosciences (NASDAQ:CLRB) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of CLRB or BDRX? 16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, CLRB or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$21.92-0.23Biodexa Pharmaceuticals$470K65.66-$7.32MN/AN/A Do analysts rate CLRB or BDRX? Cellectar Biosciences currently has a consensus target price of $375.00, suggesting a potential upside of 7,415.03%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectar Biosciences is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CLRB or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -619.70% -158.04% Biodexa Pharmaceuticals N/A N/A N/A Which has more risk & volatility, CLRB or BDRX? Cellectar Biosciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Does the media refer more to CLRB or BDRX? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.96 beat Biodexa Pharmaceuticals' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBiodexa Pharmaceuticals beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$9M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E Ratio-0.2311.7121.0120.09Price / SalesN/A30.03433.8199.01Price / CashN/A22.3936.1658.27Price / Book0.563.578.125.65Net Income-$44.58M$235.43M$3.25B$257.91M7 Day Performance2.25%-1.67%0.97%2.09%1 Month Performance-54.49%2.91%7.36%11.13%1 Year Performance-93.68%-16.44%31.31%18.40% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.2528 of 5 stars$4.99+0.4%$375.00+7,415.0%-93.7%$9MN/A-0.2310BDRXBiodexa Pharmaceuticals0.208 of 5 stars$0.98+12.1%N/AN/A$35.81M$470K0.0020High Trading VolumeAKTXAkari Therapeutics2.7868 of 5 stars$1.11-1.7%N/A-70.5%$35.75MN/A0.009Analyst ForecastTELOTelomir Pharmaceuticals3.2224 of 5 stars$1.17+0.9%$15.00+1,182.1%-69.4%$34.82MN/A-2.791News CoverageGap UpCOEPCoeptis Therapeutics0.412 of 5 stars$9.90+4.5%N/A+93.1%$34.79M$62.87K-1.712HYPDHyperion DeFi0.9457 of 5 stars$12.03-9.1%$2.00-83.4%-83.9%$34.65M$60K-0.2140Gap DownOKUROnKure Therapeutics3.1144 of 5 stars$2.50flat$32.33+1,193.3%N/A$33.78MN/A-0.48N/ANews CoveragePositive NewsMAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+742.5%$33.72MN/A0.001Gap UpKZRKezar Life Sciences4.1532 of 5 stars$4.58+1.6%$39.50+762.4%-34.3%$33.48M$7M-0.4260Analyst ForecastRNTXRein TherapeuticsN/A$1.50+4.2%N/AN/A$33.23MN/A-0.529Positive NewsGap DownCALCCalciMedica3.1593 of 5 stars$2.32+16.0%$16.00+589.7%-45.2%$32.41MN/A-1.4930News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies BDRX Alternatives AKTX Alternatives TELO Alternatives COEP Alternatives HYPD Alternatives OKUR Alternatives MAAQ Alternatives KZR Alternatives RNTX Alternatives CALC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
